胆汁淤积的血清学标志物研究进展

doi:10.20047/j.issn1673-7210.2023.12.12

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF (452 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要胆汁淤积的诊断目前面临较大挑战，研发新的标志物成为近年来胆汁淤积相关研究的热点。本文按照炎症相关标志物、非编码RNA、免疫学指标进行分类归纳，对近年来新发现的血清学标志物，包括转铁蛋白、高速泳动率族蛋白B1、髓系细胞触发受体、几丁质酶-3样蛋白-1、细胞角蛋白、微RNA、长链非编码RNA、环形RNA、核纤层蛋白B受体抗体和抗Kelch-like 12蛋白抗体、IgM等在胆汁淤积诊断和预后方面的研究结果及价值进行了分析总结，以期为后续研究提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	曹雪梅章述军

关键词 ：胆汁淤积, 胆汁淤积性肝病, 血清学标志物, 炎症

Abstract：The diagnosis of cholestasis is currently facing a major challenge, and the development of new markers has become a hot topic of cholestasis-related research in recent years. Newly discovered serological markers in recent years, including transferrin, high mobility group protein B1, myeloid cell trigger receptors, chitin Plasma-3-like protein-1, cytokeratin, microRNA, long non-coding RNA, circular RNA, lamin B receptor antibody, and anti-Kelch-like 12 protein antibody, IgM, etc. in the diagnosis and prognosis of cholestasis have been summarized in the present manuscript, that are classified into inflammation-related markers, non-coding RNAs, and immunological indicators. The results and value of the research were analyzed and summarized, in order to provide reference for follow-up research.

Key words： Cholestasis Cholestatic liver disease Serological marker Inflammation

基金资助:重庆市科卫联合医学科研项目（2020FYYX007）；
重庆市中青年医学高端人才项目（2019-181）。

通讯作者: 章述军（1980.8-），男，博士，副教授，副主任医师，硕士生导师；研究方向：肝脏疾病的诊治。

作者简介: 曹雪梅（1998.2-），女，重庆医科大学第一临床学院2021级内科学专业在读硕士研究生；研究方向：戊型肝炎、胆汁淤积性肝病。

引用本文:

曹雪梅章述军. 胆汁淤积的血清学标志物研究进展[J]. 中国医药导报, 2023, 20(12): 56-59.
CAO Xuemei ZHANG Shujun. Research advances in the study of serological markers of cholestasis. 中国医药导报, 2023, 20(12): 56-59.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.12.12 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I12/56

[1] Nie Y，Yang J，Liu S，et al. Genetic polymorphisms of human hepatic OATPs：functional consequences and effect on drug pharmacokinetics [J]. Xenobiotica，2020，50（3）：297-317.
[2] Li M，Cai S Y，Boyer JL. Mechanisms of bile acid mediated inflammation in the liver [J]. Mol Aspects Med，2017，56：45- 53.
[3] Zou M，Wang A，Wei J，et al. An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis [J]. Int Immunopharmacol，2021，92：107328.
[4] Sun C，Xiao X，Yan L，et al. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase：Is alkaline phosphatase truly a surrogate marker? [J]. J Autoimmun，2019，99：33-38.
[5] Berdichevski T，Cohen-Ezra O，Pappo O，et al. Positive antimitochondrial antibody but normal serum alkaline phosphatase levels：Could it be primary biliary cholangitis? [J]. Hepatol Res，2017，47（8）：742-746.
[6] Grytczuk A，Bauer A，Gruszewska E，et al. Changed Profile of Serum Transferrin Isoforms in Primary Biliary Cholangitis [J]. J Clin Med，2020，9（9）：2894.
[7] Simpson J，Spann KM，Phipps S. MLKL Regulates Rapid Cell Death-independent HMGB1 Release in RSV Infected Airway Epithelial Cells [J]. Front Cell Dev Biol，2022，10：890389.
[8] Kwak BJ，Choi HJ，Kim OH，et al. The Role of Phospho- c-Jun N-Terminal Kinase Expression on hepatocyte Necrosis and Autophagy in the Cholestatic Liver [J]. J Surg Res，2019，241：254-263.
[9] Jiang J，Wang X，Cheng T，et al. Dynamic Monitoring of sTREM-1 and Other Biomarkers in Acute Cholangitis [J]. Mediators Inflamm，2020，2020：8203813.
[10] Labiano I，Agirre-Lizaso A，Olaizola P，et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation [J]. J Hepatol，2022，77（4）：991- 1004.
[11] Wang S，Hu M，Qian Y，et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases [J]. Biomed Pharmacother，2020，131：110680.
[12] Temel Yuksel I，Aslan Cetin B，Koroglu N，et al. Inflammatory marker YKL-40 levels in intrahepatic cholestasis of pregnancy [J]. Gynecol Endocrinol，2019，35 （7）：635- 637.
[13] Wang P，Wu Q，Shuai ZW. Emerging role of ficolins in autoimmune diseases [J]. Pharmacol Res，2021，163：105266.
[14] Hayashi M，Abe K，Fujita M，et al. Association between serum ficolin-1 level and disease progression in primary biliary cholangitis [J]. PLoS One，2020，15（9）：e0238300.
[15] Sakellariou S，Michaelides C，Voulgaris T，et al. Keratin 7 expression in hepatic cholestatic diseases [J]. Virchows Arch，2021，479（4）：815-824.
[16] Hayashi M，Abe K，Fujita M，et al. Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis [J]. Med Mol Morphol，2018，51（3）：176-185.
[17] Olaizola P，Lee-Law PY，Arbelaiz A，et al. MicroRNAs and extracellular vesicles in cholangiopathies [J]. Biochim Biophys Acta Mol Basis Dis，2018，1864（4 Pt B）：1293-1307.
[18] Povero D，Tameda M，Eguchi A，et al. Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis [J]. Sci Rep，2022，12（1）：3027.
[19] Dong R，Ye N，Wang J，et al. Serum Exosomes MicroRNAs Are Novel Non-Invasive Bio markers of Intrahepatic Cholestasis of Pregnancy [J]. Front Endocrinol （Lausanne），2022，13：832577.
[20] Oda S，Hirabuki Y，Takeuchi T，et al. Plasma miR-218a- 5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles [J]. J Appl Toxicol，2021，41（10）：1537-1552.
[21] Li X，Liu R，Wang Y，et al. Cholangiocyte-Derived Exosomal lncRNA H19 Promotes Macrophage Activation and Hepatic Inflammation under Cholestatic Conditions [J]. Cells，2020，9（1）：190.
[22] Zheng J，Li Z，Wang T，et al. Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients [J]. Cell Physiol Biochem，2017，44（4）：1271- 1281.
[23] Lindor KD，Bowlus CL，Boyer J，et al. Primary Biliary Cholangitis：2018 Practice Guidance from the American Association for the Study of Liver Diseases [J]. Hepatology，2019，69（1）：394-419.
[24] De Liso F，Matinato C，Ronchi M，et al. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis （PBC） in anti-mitochondrial antibody （AMA）- negative PBC patients：a review of literature [J]. Clin Chem Lab Med，2017，56（1）：25-31.
[25] Ben Lamine Z，Ben Jazia I，Ben Ahmed M，et al. Anti- gp210 and anti-Sp100 antibodies in primary biliary cholangitis [J]. Arab J Gastroenterol，2021，22（4）：316- 320.
[26] Bauer A，Habior A. Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis [J]. Ann Lab Med，2019，39（3）：291-298.
[27] Bauer A，Habior A，Gawel D. Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis [J]. Biomedicines，2022，10（4）：801.
[28] Isayama H，Tazuma S，Kokudo N，et al. Clinical guidelines for primary sclerosing cholangitis 2017 [J]. J Gastroenterol，2018，53（9）：1006-1034.
[29] Wilde AB，Greverath LM，Steinhagen LM，et al. Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis [J]. J Clin Med，2022，11（3）：681.
[30] Laass MW，Ziesmann J，De Laffolie J，et al. Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children [J]. J Pediatr Gastroenterol Nutr，2022，74（4）：463-470.
[31] Ding D，Xuan G，Hu Y，et al. Immunoglobulin M：A Neglected Serum Biomarker in Treatment-Naive Primary Biliary Cholangitis With Normal Alkaline Phospha